Bamboo Joint-Like Appearance of the Stomach: A Stable Endoscopic Landmark for Crohn's Disease Regardless of Anti-Tumor Necrosis Factor alpha Treatment

被引:0
|
作者
Hashiguchi, Keiichi [1 ]
Takeshima, Fuminao [1 ]
Akazawa, Yuko [1 ]
Matsushima, Kayoko [1 ]
Minami, Hitomi [1 ]
Yamaguchi, Naoyuki [1 ]
Shiozawa, Ken [1 ]
Ohnita, Ken [1 ]
Ichikawa, Tatsuki [1 ]
Isomoto, Hajime [1 ]
Nakao, Kazuhiko [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki 852, Japan
来源
MEDICAL SCIENCE MONITOR | 2014年 / 20卷
关键词
Crohn's Disease; Diagnosis; Endoscopy; Gastrointestinal; UPPER GASTROINTESTINAL-TRACT; INFLAMMATORY-BOWEL-DISEASE; GASTRIC BODY; INFLIXIMAB; CHILDREN; THERAPY; LESIONS; CARDIA; TRIAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Bamboo joint-like appearance is a common yet easy-to-miss endoscopic finding in the stomach of patients with Crohn's disease (CD). Bamboo joint-like appearance (BJA) is characterized by swollen longitudinal folds transversed by erosive fissures or linear furrows. However, whether BJA is observed during the remission stage of CD and during the active stage is unclear. In particular, the relationship between the course of BJA and anti-tumor necrosis factor (TNF) alpha therapy has not been studied. We aimed to evaluate the course of BJA in CD patients treated with anti-TNF alpha therapy. Material/Methods: We examined 22 CD patients who underwent esophagogastroduodenal endoscopy before undergoing anti-TNF a treatment. We evaluated the changes in BJA, clinical activity using the CD activity index (CDAI), and endoscopic activity using the simple endoscopic score for CD (SES-CD) from 6 months to 1 year after anti-TNF alpha therapy. Results: Fifteen of 22 patients (68.1%) presented with BJA in the stomach, 13 of whom received follow-up esophagogastroduodenal endoscopy after anti-TNF alpha therapy. The mean CDAI and SES-CD scores significantly improved after anti-TNF alpha therapy (P<0.01). Despite the marked improvements in clinical and endoscopic findings, the BJA of the stomach remained unchanged in all the patients. Conclusions: The findings indicate that BJA is frequently observed in the stomach of CD patients, regardless of whether the patient has active disease or is in remission, even after anti-TNF alpha therapy. Thus, BJA may be a stable endoscopic landmark in CD.
引用
收藏
页码:1918 / 1924
页数:7
相关论文
共 50 条
  • [41] Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis
    Kopylov, Uri
    Ben-Horin, Shomron
    Zmora, Oded
    Eliakim, Rami
    Katz, Lior H.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) : 2404 - 2413
  • [42] Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: A case report
    Principi, M
    Di Leo, A
    Ingrosso, M
    Pisani, A
    Marangi, S
    Amoruso, A
    Panella, C
    Francavilla, A
    Ierardi, E
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2004, 26 (02) : 243 - 248
  • [43] Anti-Tumor Necrosis Factor Therapy to Prevent Crohn's Disease Recurrence After Surgery
    Herfarth, Hans H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1503 - 1506
  • [44] Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action
    Haraoui, Boulos
    Krelenbaum, Marilyn
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2009, 39 (03) : 176 - 181
  • [45] Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis
    Uchino, Motoi
    Ikeuchi, Hiroki
    Hata, Keisuke
    Minagawa, Tomohiro
    Horio, Yuki
    Kuwahara, Ryuichi
    Nakamura, Shiro
    Watanabe, Kenji
    Saruta, Masayuki
    Fujii, Toshimitsu
    Kobayashi, Taku
    Sugimoto, Ken
    Hirai, Fumihito
    Esaki, Motohiro
    Hiraoka, Sakiko
    Matsuoka, Katsuyoshi
    Shinzaki, Shinichiro
    Matsuura, Minoru
    Inoue, Nagamu
    Nakase, Hiroshi
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (04) : 864 - 872
  • [46] Is there a role of magnetic resonance imaging in deciding to stop anti-tumor necrosis factor treatment in ileal Crohn's disease?
    Gallego, Jose C.
    Echarri, Ana
    CLINICAL IMAGING, 2017, 43 : 175 - 179
  • [47] Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn's Disease
    Maria Paredes, Jose
    Ripolles, Tomas
    Cortes, Xavier
    Jesus Martinez, Maria
    Barrachina, Maria
    Gomez, Fernando
    Moreno-Osset, Eduardo
    DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (02) : 404 - 410
  • [48] Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn's Disease
    Kim, Sun
    Edelstein, Peter
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [49] Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
    Kim, Eun Sil
    Kang, Ben
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (18) : 2784 - 2797
  • [50] Possible Pulmonary Cryptococcosis in a Patient with Crohn's Disease during Anti-Tumor Necrosis Factor-Alpha Treatment: a Case Report and Literature Review
    Takazono, Takahiro
    Izumikawa, Koichi
    Yoshioka, Sumako
    Matsuo, Nobuko
    Yamakawa, Masaki
    Suyama, Naofumi
    Kohno, Shigeru
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2012, 65 (05) : 461 - 464